Halozyme to Report Third Quarter 2022 Financial and Operating Results

On October 25, 2022 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading (Press release, Halozyme, OCT 25, 2022, View Source [SID1234622355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Halozyme will host a conference call on Tuesday, November 8, 2022 at 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: View Source

A live webcast and replay of the conference call will also be available online on the investor relations section of the Halozyme Therapeutics corporate website at www.halozyme.com.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!